Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Aurinia Pharmaceuticals Inc Market Cap
Based on ratings from 7 stock analysts, the Aurinia Pharmaceuticals Inc stock price is expected to increase by 3.79% in 12 months. This is calculated by using the average 12-month stock price forecast for Aurinia Pharmaceuticals Inc. The lowest target is $8 and the highest is $13. Please note analyst price targets are not guaranteed and could be missed completely.
Aurinia Pharmaceuticals Inc has a total of 7 Wall St Analyst ratings. There are 6 buy ratings, 1 ratings, and 0 sell ratings. Since most analysts have a buy consensus rating, the expectation is that Aurinia Pharmaceuticals Inc will outperform the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of AUPH.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Olivia Brayer Cantor Fitzgerald | Overweight | $10 | Reiterates | Sep 16, 2024 |
| Olivia Brayer Cantor Fitzgerald | Overweight | $10 | Reiterates | Sep 9, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $13 | Reiterates | Sep 6, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $13 | Reiterates | Mar 1, 2024 |
| Olivia Brayer Cantor Fitzgerald | Overweight | $10 | Maintains | Feb 23, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $13 | Maintains | Feb 22, 2024 |
| Douglas Miehm RBC Capital | Outperform | $8 | Maintains | Feb 16, 2024 |
| Ed Arce HC Wainwright & Co. | Buy | $15 | Reiterates | Sep 22, 2023 |
HC Wainwright& Co. | Buy | Maintains | Aug 7, 2023 | |
| Ed Arce HC Wainwright & Co. | Buy | $15 | Maintains | Aug 7, 2023 |
| Olivia Brayer Cantor Fitzgerald | Overweight | $15 | Reiterates | Jul 6, 2023 |
| Ed Arce HC Wainwright & Co. | Buy | $14 | Reiterates | May 3, 2023 |
| Douglas Miehm RBC Capital | Outperform | $11 | Reiterates | Feb 23, 2023 |
| Douglas Miehm RBC Capital | Outperform | $11 | Maintains | Jan 4, 2023 |
| Ed Arce HC Wainwright & Co. | Buy | $14 | Maintains | Nov 7, 2022 |
| Justin Kim Oppenheimer | Perform | Downgrade | Nov 4, 2022 | |
| Douglas Miehm RBC Capital | Outperform | $10 | Maintains | Nov 4, 2022 |
| Joseph Schwartz SVB Leerink | Outperform | $12 | Maintains | Nov 4, 2022 |
| Ed Arce HC Wainwright & Co. | Buy | $26 | Maintains | Aug 9, 2022 |
| Justin Kim Oppenheimer | Outperform | $13 | Maintains | Aug 8, 2022 |
When did it IPO
2014
Staff Count
300
Country
Canada
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Peter S. Greenleaf M.B.A.
Market Cap
$1.49B
In 2023, AUPH generated $175.5M in revenue, which was a increase of 30.95% from the previous year. This can be seen as a signal that AUPH's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 18 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Aurinia has praised the updated 2024 ACR guidelines for lupus nephritis screening, treatment, and management, which may impact its market and product relevance.
Why It Matters - Aurinia's recognition of updated ACR guidelines highlights potential growth in lupus nephritis treatment, signaling a positive outlook for its market position and stock performance.
Thu, 14 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Aurinia will participate in the Jefferies London Healthcare Conference, indicating engagement with investors and potential visibility in the healthcare sector.
Why It Matters - Aurinia's participation in the Jefferies London Healthcare Conference highlights its visibility and potential investor interest, which could impact stock performance and market perception.
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Aurinia Pharmaceuticals (NASDAQ: AUPH) will present four posters at ACR 2024, focusing on lupus nephritis screening and the significance of its drug LUPKYNIS® from November 14-19 in Washington, D.C.
Why It Matters - Aurinia's acceptance of presentations at ACR 2024 highlights its commitment to addressing lupus nephritis, potentially boosting LUPKYNIS® sales and investor confidence in its growth prospects.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Aurinia Pharmaceuticals will hold its Q3 2024 earnings call on November 7, 2024, at 8:30 AM ET, featuring key executives and analysts from various financial firms.
Why It Matters - The earnings call provides insights into Aurinia Pharmaceuticals' financial performance and strategic direction, influencing stock valuation and investor sentiment.
Fri, 08 Nov 2024
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Aurinia Pharmaceuticals reported strong Q3 results, announced cost reductions, and is experiencing sales growth, with a strong balance sheet indicating potential profitability in the future.
Why It Matters - Aurinia's solid Q3 results and cost reductions signal strong financial health and growth potential, enhancing investor confidence and likely driving stock performance.
Thu, 07 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - Aurinia Pharmaceuticals reported significant year-over-year growth in Q3 2024, with $158.6 million in net product revenue and $17 million in cash flow from operations.
Why It Matters - Aurinia Pharmaceuticals' strong revenue growth and positive cash flow indicate robust business performance, potentially enhancing investor confidence and driving stock value.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
